Biogen 1Q Revenues: $2.3 billion (-7%) 1Q Earnings: $393.4 million (+1%) Comments: Multiple sclerosis (MS) product revenue, which includes TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA, was $1.1 billion, down 4%. Rare disease revenue, which includes SPINRAZA, QALSODY and SKYCLARYS, was $424 million in the quarter, down 4%. Biosimilars revenue was $197 million, up 2%. Contract manufacturing, royalty and other revenue was down 39% to $185 million. LEQEMBI launch uptake accelerated ...